Ko, Lan, M.D., Ph.D.

Ko, Lan, M.D., Ph.D.
Member, Clinical Oncology Program

Adjunct Assistant Professor, Molecular Oncology and Biomarkers 
GRU Cancer Center

 

 

Office Phone: (706) 721-8758
Office Address: CN 3155
E-mail: LKO@gru.edu
IFL Link | PubMed Link

 

Professional Overview

Lan Ko, MD, PhD, is currently an adjunct faculty member in Georgia Regents University Cancer Center, Medical College of Georgia, Augusta, Georgia, USA. Dr. Ko received her  MD (1987) from Beijing Medical University, Beijing, China, and PhD (1996) in Biochemistry at SUNY Downstate Medical Center, New York, USA. Dr. Ko did postdoctoral training at Harvard Medical School and worked for Eli Lilly and Company in Indianapolis 1999-2003). Dr. Ko came to Medical College of Georgia, Georgia Regents University in 2003 as an Assistant Professor in the Institute of Molecular Medicine and Genetics.

 

Current Research

Dr. Ko has identified two cancer genes that regulate transcription in human cancers, with publications in journals such as PNAS, Oncogene, NAR, JBC and MCB. Dr. Ko has been an invited speaker in many international conferences, and has also served as reviewer for a number of scientific journals. Dr. Ko was an award recipient from the Endocrine Society in 1999 and 2001, and was a Distinguished Cancer Scholar nominated by the Georgia Cancer Coalition. Through decades of research work as well as extensive collaborations nationally and internationally, Dr. Ko’s research team has identified two cancer-initiating genes. A breast and ovarian cancer gene at  chromosome 17q21 has both germline and recurrent somatic mutations and is mutated in hormone-producing progenitor cells. A lung cancer gene at 11q13 is genetically mutated in tumor stem cells in a large majority of sporadic lymphoma, lung cancer and head/neck cancers. Her recent effort is focused on developing anti-cancer therapies such as cancer vaccines using these two cancer gene products as anti-tumor targets, with collaborations crossing multiple institutions in Netherlands, China, and the US. The aim is to develop anti-cancer drugs targeting causative cancer-initiating stem cells to achieve patient survival without cancer relapse.